GeminIQ Website Logo

Viewing TNGX free

Subscribe for full history, 90+ metrics, screener, watchlist...

Tango Therapeutics, Inc.

TNGX

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
346158112583958705352616659
Marketable Securities Current
66822223194142158188240271282271301
Restricted Cash Current
0000001---11
Prepaid Expense And Other Assets Current
18121011988868910
Assets Current
1,032392354164190225266301328352347371
Property Plant And Equipment Net
667788899101010
Operating Lease Right Of Use Asset
343536373840394041424444
Restricted Cash Noncurrent
222222333333
Other Assets Noncurrent
000000000000
Assets
1,074436399210238274316352381406403428
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current
221233241433
Operating Lease Liability Current
333333232222
Contract With Customer Liability Current
--002319181624232627
Liabilities Current
201422184036383844434643
Operating Lease Liability Noncurrent
293031323234343535363737
Contract With Customer Liability Noncurrent
--003038455154636771
Liabilities
49445350103108117123134142149152
Temporary Equity Carrying Amount Attributable To P…
0-----------
Stockholders Equity
Common Stock Value
000000000000
Additional Paid In Capital
1,7291,040949724715708701692683674624618
Accumulated Other Comprehensive Income Loss Net Of…
-1-0000001-0-00-1
Retained Earnings Accumulated Deficit
-704-649-603-564-580-541-502-464-435-409-371-340
Stockholders Equity
1,025392346160135167200229248264253277
Liabilities And Stockholders Equity
1,074436399210238274316352381406403428
Temporary Equity Par Or Stated Value Per Share
0.0010.00100.0010.0010.00100.0010.0010.00100.001
Temporary Equity Shares Authorized
101010101010101010101010
Temporary Equity Shares Issued
000000000000
Temporary Equity Shares Outstanding
000000000000
Common Stock Par Or Stated Value Per Share
0.0010.00100.0010.0010.00100.0010.0010.00100.001
Common Stock Shares Authorized
400400400400400200200200200200200200
Common Stock Shares Issued
168144136112111108108107107107102102
Shares Outstanding
168144136112111108108107107107102102

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-20.74%15.48%8.08%---------
2025225.19%335.11%398.47%-2.89%23.44%8.47%36.20%8.24%46.19%14.44%53.12%20.26%
2024-12.52%8.47%23.26%35.67%-14.33%-32.00%21.60%-3.70%-6.17%-19.27%-40.83%-31.19%
2023-------13.20%10.74%28.97%-12.28%-15.32%-17.76%

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
50.82
27.38
16.32
8.88
4.75
6.26
6.98
8.00
7.49
8.23
7.54
8.54
Quick Ratio
49.95
26.51
15.85
8.31
4.53
6.05
6.76
7.80
7.34
8.03
7.35
8.31
Working Capital
1.01B
378.00M
332.08M
145.34M
150.08M
189.01M
228.17M
263.23M
284.54M
309.25M
300.60M
327.48M
Leverage & Debt
Debt to Equity
0.05
0.11
0.15
0.31
0.76
0.64
0.59
0.54
0.54
0.54
0.59
0.55
Interest Coverage TTM
-15.71
-18.98
-19.77
-19.15
-24.29
-19.96
-18.45
-16.80
-15.81
-16.27
-17.25
-22.06
Debt Ratio
0.05
0.10
0.13
0.24
0.43
0.39
0.37
0.35
0.35
0.35
0.37
0.35
Efficiency & Turnover
Asset Turnover TTM
0.08
0.16
0.17
0.24
0.08
0.12
0.12
0.11
0.11
0.09
0.09
0.08
Per Share Metrics
Diluted EPS TTM
-0.83
-0.75
-0.87
-0.85
-1.32
-1.20
-1.19
-1.14
-1.08
-1.03
-1.08
-1.03
Free Cash Flow Per Share TTM
-0.95
-0.99
-1.20
-0.95
-0.97
-1.23
-1.21
-1.14
-1.12
-1.13
-1.26
-1.25
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Margin Metrics
Operating Profit Margin TTM
-253.38%
-206.22%
-178.39%
-165.92%
-647.37%
-355.87%
-346.09%
-322.01%
-311.57%
-338.80%
-312.57%
-292.55%
Net Profit Margin TTM
-229.92%
-188.15%
-162.85%
-151.15%
-599.14%
-322.67%
-309.73%
-284.43%
-274.04%
-299.88%
-278.54%
-266.73%
Growth Metrics
Net Revenue Growth (1Y)
121.48%
39.04%
48.29%
53.28%
-42.85%
10.09%
15.17%
15.67%
26.16%
49.72%
46.93%
55.21%
Net Income Growth (1Y)
-15.01%
-18.93%
-22.03%
-18.54%
24.96%
18.46%
28.07%
23.34%
9.05%
0.61%
-5.95%
-1.11%
EPS Growth (1Y)
-37.31%
-37.72%
-26.69%
-20.35%
22.44%
16.18%
10.89%
10.30%
-11.05%
-17.97%
-12.66%
-10.42%
Valuation Metrics
P/E TTM
-37.87
-28.01
-10.13
-9.27
-3.89
-1.14
-2.59
-6.77
-7.98
-7.69
-9.20
-10.92
P/B TTM
4.57
7.67
2.97
5.82
4.19
0.91
1.69
3.65
3.75
3.25
3.70
3.95
P/S TTM
87.07
52.70
16.50
14.02
23.29
3.69
8.02
19.26
21.86
23.07
25.63
29.13
Market Cap
4.69B
3.00B
1.03B
932.12M
565.97M
151.11M
337.51M
835.51M
929.34M
858.88M
936.27M
1.09B
Enterprise Value
4.34B
2.85B
916.95M
873.78M
526.70M
92.68M
267.98M
782.36M
877.77M
797.72M
869.88M
1.03B
Calculated Values
Free Cash Flow TTM
-141.68M
-142.55M
-139.93M
-105.02M
-107.42M
-135.95M
-132.26M
-123.18M
-120.82M
-122.03M
-119.51M
-121.12M
Net Debt
-345.56M
-157.83M
-112.28M
-58.34M
-39.27M
-58.43M
-69.53M
-53.15M
-51.57M
-61.16M
-66.39M
-58.53M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-06-01Sale
Owner: Crystal, Adam
Title: President, R&D
Shares: 27,000
Price/Share: $22.66
Value: $611,820.00
Shares Owned: 115,743
Relationship: Officer
Ownership: Direct
2026-05-01Sale
Owner: Crystal, Adam
Title: President, R&D
Shares: 27,000
Price/Share: $21.60
Value: $583,200.00
Shares Owned: 115,743
Relationship: Officer
Ownership: Direct
2026-04-15Sale
Owner: Crystal, Adam
Title: President, R&D
Shares: 38,460
Price/Share: $25.00
Value: $961,500.00
Shares Owned: 112,622
Relationship: Officer
Ownership: Direct
2026-04-01Sale
Owner: Crystal, Adam
Title: President, R&D
Shares: 27,000
Price/Share: $21.20
Value: $572,400.00
Shares Owned: 112,622
Relationship: Officer
Ownership: Direct
2026-03-25Sale
Owner: Crystal, Adam
Title: President, R&D
Shares: 12,000
Price/Share: $20.11
Value: $241,320.00
Shares Owned: 112,622
Relationship: Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
123.92%
Inst. Shares: 177,925,086
Shares Outstanding: 143,576,292
2025-12-31
147.09%
Inst. Shares: 170,865,161
Shares Outstanding: 116,166,187
2025-09-30
122.16%
Inst. Shares: 135,551,138
Shares Outstanding: 110,966,345
2025-06-30
111.24%
Inst. Shares: 122,966,836
Shares Outstanding: 110,540,836
2025-03-31
92.19%
Inst. Shares: 101,690,392
Shares Outstanding: 110,301,256

Tango Therapeutics, Inc. (TNGX) — SEC Financial Statements & Analysis

Tango Therapeutics, Inc. (TNGX) is a pharmaceutical preparations company, incorporated in DE. Tango Therapeutics, Inc. trades on Nasdaq as: TNGX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Tango Therapeutics, Inc. reported a 121.48% year-over-year revenue growth, a Debt-to-Equity ratio of 0.05x, a Price-to-Sales (P/S) ratio of 87.07x (TTM), a Price-to-Book (P/B) ratio of 4.57x (TTM), at a market cap of $4.69B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y
121.48%
Debt To Equity
0.05x
P/S TTM
87.07x
P/B TTM
4.57x
Market Cap
$4.69B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Tango Therapeutics, Inc. in?

Tango Therapeutics, Inc. (TNGX) operates in the Pharmaceutical Preparations industry.

What is TNGX's market cap?

Tango Therapeutics, Inc. (TNGX) has a market capitalization of $4.69B as of 2026-06-30.

What exchange does TNGX trade on?

Tango Therapeutics, Inc. (TNGX) trades on the Nasdaq.

Where is Tango Therapeutics, Inc. incorporated?

Tango Therapeutics, Inc. is incorporated in DE.

Wall Street's data.
Main Street's price.